VLA printed its Q1 results this morning into one of the tightest borrow conditions it has faced all year — a miss on every line and a full-year guidance cut that sent the stock down nearly 8% on the day, even as short sellers find it increasingly difficult to press the position further.
The Q1 numbers were unambiguously weak. Revenue came in at €36.2m, well below the €46.3m consensus, while the EPS loss of €0.42 was double the €0.21 estimate. Full-year sales guidance was cut from a midpoint of roughly €189m to around €179m, still above the €192.8m analyst estimate prior to the print — confirming that the Street was already positioned for a bad number and still got surprised. The stock closed at €2.53 on Tuesday and fell another 7.6% today, extending its one-month loss to more than 5%, though a sharp 10.2% rebound earlier in the week softened the net weekly picture.
The lending market tells the clearest structural story this week. Borrow availability has tightened to near the worst level of the past year. Short interest is running at 5.9% of the free float — broadly stable over the past month, inching higher from a trough of 5.5% in late April back to its current level. That steadiness masks the pressure underneath: the lending pool is almost fully exhausted, with availability near its 52-week floor. Cost to borrow has climbed 51% over the past month to 11.4% APR, and while it has oscillated in a tight band of 10–12% for most of April and May, the persistence of that elevated rate reflects how competitive the borrow has become. The ORTEX short score of 68.6 is consistent with high existing pressure — any new short would face a crowded and expensive trade.
That positioning context mattered going into today's print. The two most recent earnings events on record delivered severe reactions: a 38% one-day decline on March 20 and a 5% drop on March 18, with both events carrying five-day moves of roughly -38% to -40%. Today's 7.6% fall is — in that context — a relatively contained response, though investors arriving late to the thesis will note the stock has already lost a very large portion of its value over the prior two events. The March 20 decline followed what was announced as a restructuring and has been followed by a legal investigation headline circulating ahead of today's Q1 release.
On the ownership side, Bpifrance Participations trimmed its position by 891,739 shares as of early March, and filed a Schedule 13D/A with the SEC on May 12 — the day before results. BlackRock, by contrast, added 357,252 shares in the period ending April 30, and CDC Croissance added 364,705. The divergence between the state-backed French investors — one reducing, one adding — gives no clean directional read. The single sell-side rating on record is a Sell with a mean target of €5.79, which is substantially above the current €2.53 price. Given that rating data is now 21 days old and has not been updated since the guidance cut, that target should be treated as stale rather than current consensus.
The next scheduled event is a H1 result on August 13. What traders will watch between now and then is whether the guidance reduction proves a floor or a precursor to another revision — the gap between the new top-end guidance and the prior consensus was already widening before today, and the Q1 revenue shortfall leaves no cushion against further commercial disappointment.
See the live data behind this article on ORTEX.
Open VLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
